Dr. Reddy’s is introducing lenalidomide capsules, a generic of Revlimid. With this volume-limited launch, Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for ...

FDA approved Adcetris, Revlimid, and Rituxan for relapsed/refractory LBCL patients ineligible for auto-HSCT or CAR-T therapy, based on ECHELON-3 trial results. The combination therapy showed ...

The Food and Drug Administration has cleared Cipla’s lenalidomide capsules in dosage strengths of 5 mg, 10 mg, 15 mg and 25 mg. Cipla’s lenalidomide capsules are the generic of Bristol Myers Squibb’s ...

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

BOSTON, Dec 18 (Reuters) - Celgene Corp said on Friday that initial results from a clinical trial showed multiple myeloma patients who took its drug Revlimid following a stem cell transplant had a 58 ...

Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...

Australian biotech HaemaLogix has posted phase 2b data that show its monoclonal antibody “significantly” improves response rates for multiple myeloma patients when paired with Revlimid. The 40-person ...

The Mayo Clinic and LifePoint Health believe that collusion within the pharmaceutical industry forced their organizations to overpay for the multiple myeloma drug Revlimid and are petitioning the ...

Bristol-Myers BMY reported mixed second-quarter results below our projections largely due to lower-than-expected sales of cancer drug Revlimid. Since Revlimid has a short period of exclusivity left, ...

BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.

In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.